Cargando…
The EGFR‐P38 MAPK axis up‐regulates PD‐L1 through miR‐675‐5p and down‐regulates HLA‐ABC via hexokinase‐2 in hepatocellular carcinoma cells
BACKGROUND: Immunotherapy has been shown to be a promising strategy against human cancers. A better understanding of the immune regulation in hepatocellular carcinoma (HCC) could help the development of immunotherapy against HCC. The epidermal growth factor receptor (EGFR) signaling is frequently ac...
Autores principales: | , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley and Sons Inc.
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7819566/ https://www.ncbi.nlm.nih.gov/pubmed/34236149 http://dx.doi.org/10.1002/cac2.12117 |
_version_ | 1783639032678318080 |
---|---|
author | Liu, Zongcai Ning, Fen Cai, Yanna Sheng, Huiying Zheng, Ruidan Yin, Xi Lu, Zhikun Su, Ling Chen, Xiaodan Zeng, Chunhua Wang, Haifang Liu, Li |
author_facet | Liu, Zongcai Ning, Fen Cai, Yanna Sheng, Huiying Zheng, Ruidan Yin, Xi Lu, Zhikun Su, Ling Chen, Xiaodan Zeng, Chunhua Wang, Haifang Liu, Li |
author_sort | Liu, Zongcai |
collection | PubMed |
description | BACKGROUND: Immunotherapy has been shown to be a promising strategy against human cancers. A better understanding of the immune regulation in hepatocellular carcinoma (HCC) could help the development of immunotherapy against HCC. The epidermal growth factor receptor (EGFR) signaling is frequently activated in HCC and plays important roles in tumorigenesis. However, its role in HCC immunity is still largely unknown. This study aimed to investigate the impact of EGFR signaling on programmed death‐ligand 1 (PD‐L1) and human leukocyte antigen class‐I (HLA‐I) expression in HCC cells and its underlying mechanisms. METHODS: The expression of phosphorylated EGFR (p‐EGFR), PD‐L1, and HLA‐I (HLA‐ABC) in HCC specimens was detected by immunohistochemistry, and their correlations were analyzed. PD‐L1 and HLA‐ABC expression in EGFR‐activated HCC cells were detected by quantitative real‐time PCR, Western blotting, and flow cytometry, and T cell‐mediated lysis was performed to test the immunosuppressive effects of PD‐L1 and HLA‐ABC alterations in HCC cells. Furthermore, the underlying mechanisms of EGFR activation‐induced PD‐L1 up‐regulation and HLA‐ABC down‐regulation were explored by animal experiments, luciferase reporter assay, and gene gain‐ and loss‐of‐function studies. RESULTS: p‐EGFR was positively correlated with PD‐L1 and negatively correlated with HLA‐ABC expression in HCCs. EGFR activation by its ligand EGF up‐regulated PD‐L1 and down‐regulated HLA‐ABC in HCC cells, which was functionally important and could be abolished by the EGFR inhibitor, gefitinib, both in vitro and in vivo. Mechanistically, enhanced P38 mitogen‐activated protein kinase (MAPK) activation down‐regulated microRNA‐675‐5p (miR‐675‐5p) and up‐regulated glycolysis‐related enzyme hexokinase 2 (HK2); miR‐675‐5p down‐regulation enhanced the stability of PD‐L1 mRNA probably via the 3’‐untranslated region (3’‐UTR) of PD‐L1 and thereby caused PD‐L1 accumulation, and HK2 up‐regulation enhanced aerobic glycolysis and mediated a decrease in HLA‐ABC. CONCLUSIONS: The EGFR‐P38 MAPK axis could up‐regulate PD‐L1 through miR‐675‐5p and down‐regulate HLA‐ABC via HK2 in HCC cells. Our study reveals a novel signaling network that may cause immune suppression in HCC and suggests that EGFR signaling can be targeted for HCC immunotherapy. |
format | Online Article Text |
id | pubmed-7819566 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | John Wiley and Sons Inc. |
record_format | MEDLINE/PubMed |
spelling | pubmed-78195662021-01-29 The EGFR‐P38 MAPK axis up‐regulates PD‐L1 through miR‐675‐5p and down‐regulates HLA‐ABC via hexokinase‐2 in hepatocellular carcinoma cells Liu, Zongcai Ning, Fen Cai, Yanna Sheng, Huiying Zheng, Ruidan Yin, Xi Lu, Zhikun Su, Ling Chen, Xiaodan Zeng, Chunhua Wang, Haifang Liu, Li Cancer Commun (Lond) Original Articles BACKGROUND: Immunotherapy has been shown to be a promising strategy against human cancers. A better understanding of the immune regulation in hepatocellular carcinoma (HCC) could help the development of immunotherapy against HCC. The epidermal growth factor receptor (EGFR) signaling is frequently activated in HCC and plays important roles in tumorigenesis. However, its role in HCC immunity is still largely unknown. This study aimed to investigate the impact of EGFR signaling on programmed death‐ligand 1 (PD‐L1) and human leukocyte antigen class‐I (HLA‐I) expression in HCC cells and its underlying mechanisms. METHODS: The expression of phosphorylated EGFR (p‐EGFR), PD‐L1, and HLA‐I (HLA‐ABC) in HCC specimens was detected by immunohistochemistry, and their correlations were analyzed. PD‐L1 and HLA‐ABC expression in EGFR‐activated HCC cells were detected by quantitative real‐time PCR, Western blotting, and flow cytometry, and T cell‐mediated lysis was performed to test the immunosuppressive effects of PD‐L1 and HLA‐ABC alterations in HCC cells. Furthermore, the underlying mechanisms of EGFR activation‐induced PD‐L1 up‐regulation and HLA‐ABC down‐regulation were explored by animal experiments, luciferase reporter assay, and gene gain‐ and loss‐of‐function studies. RESULTS: p‐EGFR was positively correlated with PD‐L1 and negatively correlated with HLA‐ABC expression in HCCs. EGFR activation by its ligand EGF up‐regulated PD‐L1 and down‐regulated HLA‐ABC in HCC cells, which was functionally important and could be abolished by the EGFR inhibitor, gefitinib, both in vitro and in vivo. Mechanistically, enhanced P38 mitogen‐activated protein kinase (MAPK) activation down‐regulated microRNA‐675‐5p (miR‐675‐5p) and up‐regulated glycolysis‐related enzyme hexokinase 2 (HK2); miR‐675‐5p down‐regulation enhanced the stability of PD‐L1 mRNA probably via the 3’‐untranslated region (3’‐UTR) of PD‐L1 and thereby caused PD‐L1 accumulation, and HK2 up‐regulation enhanced aerobic glycolysis and mediated a decrease in HLA‐ABC. CONCLUSIONS: The EGFR‐P38 MAPK axis could up‐regulate PD‐L1 through miR‐675‐5p and down‐regulate HLA‐ABC via HK2 in HCC cells. Our study reveals a novel signaling network that may cause immune suppression in HCC and suggests that EGFR signaling can be targeted for HCC immunotherapy. John Wiley and Sons Inc. 2021-01-01 /pmc/articles/PMC7819566/ /pubmed/34236149 http://dx.doi.org/10.1002/cac2.12117 Text en © 2020 The Authors. Cancer Communications published by John Wiley & Sons Australia, Ltd. on behalf of Sun Yat‐sen University Cancer Center This is an open access article under the terms of the http://creativecommons.org/licenses/by-nc-nd/4.0/ License, which permits use and distribution in any medium, provided the original work is properly cited, the use is non‐commercial and no modifications or adaptations are made. |
spellingShingle | Original Articles Liu, Zongcai Ning, Fen Cai, Yanna Sheng, Huiying Zheng, Ruidan Yin, Xi Lu, Zhikun Su, Ling Chen, Xiaodan Zeng, Chunhua Wang, Haifang Liu, Li The EGFR‐P38 MAPK axis up‐regulates PD‐L1 through miR‐675‐5p and down‐regulates HLA‐ABC via hexokinase‐2 in hepatocellular carcinoma cells |
title | The EGFR‐P38 MAPK axis up‐regulates PD‐L1 through miR‐675‐5p and down‐regulates HLA‐ABC via hexokinase‐2 in hepatocellular carcinoma cells |
title_full | The EGFR‐P38 MAPK axis up‐regulates PD‐L1 through miR‐675‐5p and down‐regulates HLA‐ABC via hexokinase‐2 in hepatocellular carcinoma cells |
title_fullStr | The EGFR‐P38 MAPK axis up‐regulates PD‐L1 through miR‐675‐5p and down‐regulates HLA‐ABC via hexokinase‐2 in hepatocellular carcinoma cells |
title_full_unstemmed | The EGFR‐P38 MAPK axis up‐regulates PD‐L1 through miR‐675‐5p and down‐regulates HLA‐ABC via hexokinase‐2 in hepatocellular carcinoma cells |
title_short | The EGFR‐P38 MAPK axis up‐regulates PD‐L1 through miR‐675‐5p and down‐regulates HLA‐ABC via hexokinase‐2 in hepatocellular carcinoma cells |
title_sort | egfr‐p38 mapk axis up‐regulates pd‐l1 through mir‐675‐5p and down‐regulates hla‐abc via hexokinase‐2 in hepatocellular carcinoma cells |
topic | Original Articles |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7819566/ https://www.ncbi.nlm.nih.gov/pubmed/34236149 http://dx.doi.org/10.1002/cac2.12117 |
work_keys_str_mv | AT liuzongcai theegfrp38mapkaxisupregulatespdl1throughmir6755panddownregulateshlaabcviahexokinase2inhepatocellularcarcinomacells AT ningfen theegfrp38mapkaxisupregulatespdl1throughmir6755panddownregulateshlaabcviahexokinase2inhepatocellularcarcinomacells AT caiyanna theegfrp38mapkaxisupregulatespdl1throughmir6755panddownregulateshlaabcviahexokinase2inhepatocellularcarcinomacells AT shenghuiying theegfrp38mapkaxisupregulatespdl1throughmir6755panddownregulateshlaabcviahexokinase2inhepatocellularcarcinomacells AT zhengruidan theegfrp38mapkaxisupregulatespdl1throughmir6755panddownregulateshlaabcviahexokinase2inhepatocellularcarcinomacells AT yinxi theegfrp38mapkaxisupregulatespdl1throughmir6755panddownregulateshlaabcviahexokinase2inhepatocellularcarcinomacells AT luzhikun theegfrp38mapkaxisupregulatespdl1throughmir6755panddownregulateshlaabcviahexokinase2inhepatocellularcarcinomacells AT suling theegfrp38mapkaxisupregulatespdl1throughmir6755panddownregulateshlaabcviahexokinase2inhepatocellularcarcinomacells AT chenxiaodan theegfrp38mapkaxisupregulatespdl1throughmir6755panddownregulateshlaabcviahexokinase2inhepatocellularcarcinomacells AT zengchunhua theegfrp38mapkaxisupregulatespdl1throughmir6755panddownregulateshlaabcviahexokinase2inhepatocellularcarcinomacells AT wanghaifang theegfrp38mapkaxisupregulatespdl1throughmir6755panddownregulateshlaabcviahexokinase2inhepatocellularcarcinomacells AT liuli theegfrp38mapkaxisupregulatespdl1throughmir6755panddownregulateshlaabcviahexokinase2inhepatocellularcarcinomacells AT liuzongcai egfrp38mapkaxisupregulatespdl1throughmir6755panddownregulateshlaabcviahexokinase2inhepatocellularcarcinomacells AT ningfen egfrp38mapkaxisupregulatespdl1throughmir6755panddownregulateshlaabcviahexokinase2inhepatocellularcarcinomacells AT caiyanna egfrp38mapkaxisupregulatespdl1throughmir6755panddownregulateshlaabcviahexokinase2inhepatocellularcarcinomacells AT shenghuiying egfrp38mapkaxisupregulatespdl1throughmir6755panddownregulateshlaabcviahexokinase2inhepatocellularcarcinomacells AT zhengruidan egfrp38mapkaxisupregulatespdl1throughmir6755panddownregulateshlaabcviahexokinase2inhepatocellularcarcinomacells AT yinxi egfrp38mapkaxisupregulatespdl1throughmir6755panddownregulateshlaabcviahexokinase2inhepatocellularcarcinomacells AT luzhikun egfrp38mapkaxisupregulatespdl1throughmir6755panddownregulateshlaabcviahexokinase2inhepatocellularcarcinomacells AT suling egfrp38mapkaxisupregulatespdl1throughmir6755panddownregulateshlaabcviahexokinase2inhepatocellularcarcinomacells AT chenxiaodan egfrp38mapkaxisupregulatespdl1throughmir6755panddownregulateshlaabcviahexokinase2inhepatocellularcarcinomacells AT zengchunhua egfrp38mapkaxisupregulatespdl1throughmir6755panddownregulateshlaabcviahexokinase2inhepatocellularcarcinomacells AT wanghaifang egfrp38mapkaxisupregulatespdl1throughmir6755panddownregulateshlaabcviahexokinase2inhepatocellularcarcinomacells AT liuli egfrp38mapkaxisupregulatespdl1throughmir6755panddownregulateshlaabcviahexokinase2inhepatocellularcarcinomacells |